In a recent case trial follow up of a patient with a recurring glioblastoma (GBM) tumor who had been undergoing NEO100 intranasal treatment, a postsurgical biopsy of the tumor showed the definitive presence of NEO100 which is the first in-human clinical evidence of the viability of NEO100 intranasal delivery as a delivery mechanism for chemotherapeutic […]